Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

SNTI

Senti Biosciences Inc.

Apr 26 • 09:33AM ET

0.3067

Dollar change +0.0280
Percentage change 10.05	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: ARKG VXF VTI ARKG

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.60	Insider Own	40.16%	Shs Outstand	45.70M	Perf Week	-0.26%
Market Cap	14.03M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	27.38M	Perf Month	-21.36%
Income	-71.06M	PEG	-	EPS next Q	-	Inst Own	8.66%	Short Float	0.60%	Perf Quarter	-30.14%
Sales	2.56M	P/S	5.48	EPS this Y	-	Inst Trans	-4.56%	Short Ratio	2.07	Perf Half Y	2.23%
Book/sh	1.46	P/B	0.21	EPS next Y	-	ROA	-61.76%	Short Interest	0.17M	Perf Year	-69.33%
Cash/sh	0.79	P/C	0.39	EPS next 5Y	-	ROE	-95.50%	52W Range	0.27 - 1.10	Perf YTD	-53.53%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-70.74%	52W High	-72.12%	Beta	3.01
Dividend TTM	-	Quick Ratio	5.62	Sales past 5Y	7.49%	Gross Margin	-111.99%	52W Low	13.55%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	5.62	EPS Y/Y TTM	5.91%	Oper. Margin	-2970.75%	RSI (14)	43.40	Volatility	10.47% 10.81%
Employees	48	Debt/Eq	0.56	Sales Y/Y TTM	-19.54%	Profit Margin	-2774.62%	Recom	3.00	Target Price	2.00
Option/Short	No / Yes	LT Debt/Eq	0.50	EPS Q/Q	-0.87%	Payout	-	Rel Volume	0.11	Prev Close	0.28
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-100.00%	Earnings	Mar 21 AMC	Avg Volume	79.88K	Price	0.31
SMA20	-7.32%	SMA50	-19.21%	SMA200	-37.02%	Trades		Volume	546	Change	10.05%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-22	Initiated	Morgan Stanley	Equal-Weight	$7.50

Mar-21-24 10:53PM	SNTI Stock Earnings: Senti Biosciences Misses EPS for Q4 2023 (InvestorPlace) +6.82%
04:05PM	Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights (GlobeNewswire)
Jan-05-24 04:05PM	Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program (GlobeNewswire) -6.15%
Dec-26-23 11:32AM	Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate (Zacks) +5.48%
Dec-22-23 12:12PM	Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today? (Benzinga) +18.45%
06:30AM	Loading…
06:30AM	Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia (GlobeNewswire)
Nov-13-23 04:15PM	Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates (GlobeNewswire) -16.31%
Nov-07-23 07:54AM	Why Is Senti Biosciences (SNTI) Stock Up 140% Today? (InvestorPlace) +78.08%
Nov-06-23 04:05PM	Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China (GlobeNewswire)
Oct-31-23 09:06AM	Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-27-23 09:05AM	Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting (GlobeNewswire)
Sep-26-23 04:05PM	Senti Bio to Participate in Upcoming Conferences (GlobeNewswire)
Sep-05-23 08:30AM	Senti Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-11-23 09:50AM	Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:35AM	Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates (GlobeNewswire)
08:35AM	Loading…
Aug-10-23 08:35AM	Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners (GlobeNewswire)
Jun-05-23 08:04AM	Here's Why Senti Biosciences (NASDAQ:SNTI) Must Use Its Cash Wisely (Simply Wall St.)
May-20-23 08:05AM	Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (GlobeNewswire)
May-09-23 04:05PM	Senti Bio Announces First Quarter 2023 Results and Pipeline Updates (GlobeNewswire)
May-02-23 04:45PM	Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting (GlobeNewswire)
Apr-17-23 08:45AM	Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting (GlobeNewswire) -6.54%
Apr-14-23 09:00AM	Senti Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-22-23 05:09PM	Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights (GlobeNewswire)
Mar-14-23 04:35PM	Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting (GlobeNewswire)
Feb-06-23 06:26AM	Investors in Senti Biosciences (NASDAQ:SNTI) have unfortunately lost 82% over the last year (Simply Wall St.)
Feb-03-23 04:05PM	Senti Biosciences Announces New Employment Inducement Grants (GlobeNewswire)
Feb-01-23 04:05PM	Senti Bio to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-27-23 08:00AM	Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance (GlobeNewswire)
Dec-27-22 06:53AM	We Think Senti Biosciences (NASDAQ:SNTI) Needs To Drive Business Growth Carefully (Simply Wall St.) -6.72%
Dec-19-22 07:55AM	Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.23%
09:00AM	Loading…
Dec-11-22 09:00AM	Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event (GlobeNewswire)
Nov-23-22 07:55AM	Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting (GlobeNewswire) +6.16%
Nov-16-22 06:16AM	Senti Biosciences Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-10-22 07:55AM	Senti Bio Reports Third Quarter Financial Results and Pipeline Updates (GlobeNewswire) +8.30%
Nov-03-22 09:05AM	Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting (GlobeNewswire) +7.14%
Oct-28-22 04:05PM	Senti Bio Announces New Employment Inducement Grants (GlobeNewswire)
Oct-05-22 08:01AM	Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting (GlobeNewswire)
Oct-04-22 07:04AM	Positive week for Senti Biosciences, Inc. (NASDAQ:SNTI) institutional investors who lost 75% over the past year (Simply Wall St.) +105.60%
Sep-20-22 04:02PM	Senti Bio to Participate in Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-06-22 04:01PM	Senti Bio to Present at Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire)
Sep-01-22 11:57AM	Chardan Announces Launch of ChEF (Chardan Equity Facility) (PR Newswire)
Aug-19-22 04:05PM	Senti Biosciences Announces New Employment Inducement Grants (GlobeNewswire)
Aug-15-22 04:05PM	Senti Bio Reports Second Quarter Financial Results and Business Updates (GlobeNewswire)
Jul-30-22 09:13AM	Senti Biosciences (NASDAQ:SNTI) shareholders are up 68% this past week, but still in the red over the last year (Simply Wall St.)
Jul-01-22 10:39AM	Bay Area's stream of new public companies has slowed to a weak trickle (American City Business Journals)
Jun-13-22 12:55PM	Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) -45.00%

Senti Biosciences, Inc. is a biotechnology company. It engages in the business of developing next-generation cell and gene therapies engineered with a gene circuit platform technology to fight challenging diseases. The company was founded by Timothy K. Lu, Wilson Wong, and Philip Lee on June 9, 2016 and is headquartered in South San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNTI

Senti Biosciences Inc.

Upgrade your FINVIZ experience